6-month results of the BIOLUX P-II study at a glance

Endpoints	**Defined as**	**Passeo 18-Lux DRB-Group**	**PTA-Group**
Primary clinical endpoint	MAE after 30 days	0.0%	8.3%
Efficacy primary endpoint data	TLP after 6 months	84.3%	75.9%
Secondary endpoint	Change in Rutherford Classification after 6 months	9 out of 26 patients ranked in class 5	16 out of 26 patients ranked in class 5
Secondary endpoint	Amputation rate after 6 months	3.3%	5.7%